Mar 18, 2026 by Danny Vena, CPANvidia Prepares for a Triumphant Return to China's Artificial Intelligence (AI) Chip MarketThe chipmaker has overcome numerous obstacles to sell its AI chips in China.
Mar 18, 2026 by Dan CaplingerThis ETF Should Be Crushing the Market. Here's Why It Might Finally Be About ToIt's been a tough time for the investing strategy this fund uses.
Mar 18, 2026 by Matt DiLallo3 Monster Dividend Stocks to Hold for the Next 10 YearsThese dividend stocks could generate monster total returns over the next decade.
Mar 18, 2026 by Dan CaplingerThis ETF Should Be Crushing the Market. Here's Why It Might Finally Be About ToIt's been a tough time for the investing strategy this fund uses.
Mar 18, 2026 by Thomas NielOpendoor Technologies Stock Is Down 50%. Is It Finally Time to Buy?Fundamentals alone won't get this former highflier back to prior highs.
Mar 18, 2026 by Jake LerchREET Delivers a Higher Yield, But ICF Provides Greater Exposure to the U.S. REIT MarketFee structure, yield, and diversification set these two real estate ETFs apart—here’s what investors should weigh before choosing.
Mar 18, 2026 by Andy GouldVNQI vs. RWX: Which International Real Estate ETF Belongs in Your Portfolio?See how VNQI and RWX differ on fees, diversification, and portfolio focus -- all key factors for international real estate ETF investors.
Mar 18, 2026 by Matt DiLallo3 Monster Dividend Stocks to Hold for the Next 10 YearsThese dividend stocks could generate monster total returns over the next decade.
Mar 18, 2026 by Jonathan PoncianoThis New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock GainAxsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.
Mar 18, 2026 by Geoffrey SeilerThe Best Stocks to Invest $10,000 in Right NowThese three AI stocks look like great buys at the moment.
Mar 18, 2026 by Jonathan PoncianoSionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
Mar 18, 2026 by Danny Vena, CPANvidia Prepares for a Triumphant Return to China's Artificial Intelligence (AI) Chip MarketThe chipmaker has overcome numerous obstacles to sell its AI chips in China.
Mar 18, 2026 by Seena HassounaWhat to Make of VR Adviser's Big Ocular Therapeutix Sell-DownThis ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.
Mar 18, 2026 by Jonathan PoncianoThis $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage NamesThis clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
Mar 18, 2026 by Matt Frankel, CFPThe 3 Things That Matter Most for MercadoLibre Right NowAfter MercadoLibre's latest earnings, there are a few important things to watch.
Mar 18, 2026 by Rick MunarrizA Letter to Disney's New CEOJosh D'Amaro takes over the media giant at this week's annual shareholder meeting. It's an exciting and frightening opportunity.
Mar 18, 2026 by Sara AppinoRWR vs. REET: Same Blue-Chip REIT Foundation, Different Geographic StrategiesCompare how global diversification, fund size, and cost structure set these two real estate ETFs apart for investors.
Mar 18, 2026 by Matt DiLalloOil Stocks Could Reap a $60 Billion Windfall if Crude Prices Remain Elevated This YearOil companies could produce even bigger free cash flow gushers if oil prices stay high.
Mar 18, 2026 by Christy BieberThis Was My Biggest Retirement Savings MistakeMy mistake is far too common.
Mar 18, 2026 by Adam Levy1 Can't-Miss Artificial Intelligence (AI) Stock to Buy With $100 Right NowThe market is underappreciating the growth potential for this chipmaker.
Mar 18, 2026 by Jonathan PoncianoThis Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very BullishThis clinical-stage biotech develops therapies for CML, NASH, and obesity.
Mar 18, 2026 by John BromelsThe Trump Administration Just Rewarded Archer Aviation and Joby Aviation. Which One Is the Big Winner?The rival eVTOL air taxi companies agree that this is a big deal. But which one got the short end of the stick?
Mar 18, 2026 by Sara AppinoREET vs. HAUZ: One Fund Anchors in U.S. REITs, the Other Invests Entirely AbroadExpense ratios, dividend yields, and geographic focus set these real estate ETFs apart for investors seeking tailored global exposure.
